Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 30 Jun 2017 Planned End Date changed from 31 Jan 2018 to 31 Aug 2017.
- 30 Jun 2017 Planned primary completion date changed from 31 Jan 2018 to 31 Aug 2017.
- 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.